Quick Answer
Cartesian Therapeutics, Inc. reported Operating Income of -$143.41 million for fiscal year 2025.
Cartesian Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$143.41M | -226.7% |
| 2024 | -$43.90M | +49.2% |
| 2023 | -$86.42M | -694.4% |
| 2022 | $14.54M | +416.2% |
| 2021 | -$4.60M | +91.9% |
| 2020 | -$56.82M | -8.3% |
| 2019 | -$52.45M | +19.3% |
| 2018 | -$65.02M | -1.9% |
| 2017 | -$63.78M | -84.0% |
| 2016 | -$34.67M | -37.0% |
| 2015 | -$25.30M | -64.3% |
| 2014 | -$15.40M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.07M | -19.9% | +3.4% |
| June 30, 2025 | -$21.81M | -258.5% | +0.4% |
| March 31, 2025 | -$21.89M | -64.0% | -24.5% |
| September 30, 2024 | -$17.57M | -34.5% | -227.8% |
| June 30, 2024 | $13.76M | +173.8% | +203.1% |
| March 31, 2024 | -$13.35M | +27.4% | -2.2% |
| September 30, 2023 | -$13.06M | -717.1% | +29.9% |
| June 30, 2023 | -$18.64M | -234.5% | -1.4% |
- Cartesian Therapeutics, Inc. showed a decrease of -226.7% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Cartesian Therapeutics, Inc.’s operating income has declined by 831.3% (from -$15.40 million to -$143.41 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: